APC gene hypermethylation and prostate cancer: A systematic review and meta-analysis

European Journal of Human Genetics

Volumn 21, Issue 9, 2013, Pages 929-935

  Chen, Yang ^a   Li, Jie ^a   Yu, Xiaoxiang ^b   Li, Shuai ^a   Zhang, Xuerong ^a   Mo, Zengnan ^a,c   Hu, Yanling ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b The 303rd Hospital of PLA   (China)

^c FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

adenomatous polyposis coli; hypermethylation; methylation; prostate cancer

Indexed keywords

APC PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; EMBASE; GLEASON SCORE; HUMAN; MEDLINE; META ANALYSIS; METHYLATION; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ADENOMATOUS POLYPOSIS COLI PROTEIN; CASE-CONTROL STUDIES; DNA METHYLATION; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84882449183     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.281     Document Type: Article

References (55)

1. Parkin DM, Bray F, Ferlay J et al: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 174-108.
2. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
4. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
5. Zaridze DG, Boyle P, Smans M: International trends in prostatic cancer. Int J Cancer 1984; 33: 223-230.
6. Cooner WH, Mosley BR, Rutherford Jr CL et al: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990. J Urol 2002; 167: 966-973.
7. Stamey TA, Caldwell M, McNeal JE et al: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297-1301.
8. Eads CA, Danenberg KD, Kawakami K et al: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28: E32.
9. Cho NY, Kim JH, Moon KC et al: Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch 2009; 454: 17-23.
10. Costa VL, Henrique R, Jerónimo C: Epigenetic markers for molecular detection of prostate cancer. Dis Markers 2007; 23: 31-41.
11. Hoque MO, Topaloglu O, Begum S et al: Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005; 23: 6569-6575.
12. Rogers CG, Gonzalgo ML, Yan G et al: High concordance of gene methylation in postdigital rectal examination and post-biopsy urine samples for prostate cancer detection. J Urol 2006; 176: 2280-2284.
13. Rouprêt M, Hupertan V, Catto JW et al: Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 2008; 122: 952-956.
14. Rouprêt M, Hupertan V, Yates DR et al: Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007; 13: 1720-1725.
15. Vener T, Derecho C, Baden J et al: Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 2008; 54: 874-882.
16. Yoon HY, Kim SK, Kim YW et al: Combined hypermethylation of APC and GSTP1 as a Molecular marker for prostate cancer: quantitative pyrosequencing analysis. J Biomol Screen 2012; 17: 987-992.
17. Kang GH, Lee S, Lee HJ et al: Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202: 233-240.
18. Bastian PJ, Ellinger J, Heukamp LC et al: Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007; 51: 665-674.
19. Ellinger J, Bastian PJ, Jurgan T et al: CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008; 71: 161-167.
20. Maruyama R, Toyooka S, Toyooka KO et al: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8: 514-519.
21. Jerónimo C, Henrique R, Hoque MO et al: A Quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 8472-8478.
22. Tokumaru Y, Harden SV, Sun DI et al: Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004; 10: 5518-5522.
23. Bastian PJ, Ellinger J, Wellmann A et al: Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005; 11: 4097-4106.
24. Enokida H, Shiina H, Urakami S et al: Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005; 11: 6582-6588.
25. Henrique R, Jerónimo C, Teixeira MR et al: Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006; 4: 1-8.
26. Yegnasubramanian S, Kowalski J, Gonzalgo ML et al: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64: 1975-1986.
27. Cho NY, Kim BH, Choi M et al: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007; 211: 269-277.
28. Vasiljević N, Wu K, Brentnall AR et al: Absolute quantitation of DNAmethylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 2011; 30: 151-161.
29. Trock BJ, Brotzman MJ, Mangold LA et al: Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 2012; 110: 56-62.
30. Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
31. Midgette AS, Stukel TA, Littenberg B: A meta-analytic method for summarizing diagnostic test performances: receiver-operating-characteristic- summary point estimates. Med Decis Making 1993; 13: 253-257.
32. Wu T, Giovannucci E, Welge J et al: Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 2011; 105: 65-73.
33. Schwarzenbach H, Chun FK, Isbarn H et al: Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. J Cancer Res Clin Oncol 2011; 137: 811-819.
34. Okegawa T, Nutahara K, Higashihara E: Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol 2010; 17: 466-475.
35. Phé V, Cussenot O, Rouprêt M: Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int 2009; 104: 896-901.
36. Phé V, Cussenot O, Rouprêt M: Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010; 105: 1364-1370.
37. Baden J, Green G, Painter J et al: Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 2009; 182: 1186-1193.
38. Baden J, Adams S, Astacio T et al: Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0ng/ml using an investigational prostate cancer methylation assay. J Urol 2011; 186: 2101-2106.
39. Florl AR, Steinhoff C, Müller M et al: Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004; 91: 985-994.
40. Van Neste L, Bigley J, Toll A et al: A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol 2012; 12: 16.
41. Stewart GD, Van Neste L, Delvenne P et al: Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC Study. J Urol 2012; S0022-5347: 04906-3.
42. Richiardi L, Fiano V, Vizzini L et al: Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009; 27: 3161-3168.
43. Padar A, Sathyanarayana UG, Suzuki M et al: Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res 2003; 9: 4730-4734.
44. Costa VL, Henrique R, Ribeiro FR et al: Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics 2010; 5: 343-351.
45. Liu L, Kron KJ, Pethe VV et al: Association of tissue promoter methylation levels of APC, TGFb2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 2011; 129: 2454-2462.
46. Steiner I, Jung K, Schatz P et al: Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiology 2010; 77: 260-266.
47. Troyer DA, Lucia MS, de Bruïne AP et al: Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev 2009; 18: 2717-2722.
48. Gillio-Tos A, Fiano V, Zugna D et al: DNA methyltransferase 3b (DNMT3b), tumor tissue DNA methylation, Gleason score, and prostate cancer mortality: investigating causal relationships. Cancer Causes Control 2012; 23: 1549-1555.
49. Rosenbaum E, Hoque MO, Cohen Y et al: Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005; 11: 8321-8325.
50. Delgado-Cruzata L, Hruby GW, Gonzalez K et al: DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol 2012; 31: 187-192.
51. Henrique R, Ribeiro FR, Fonseca D et al: High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007; 13: 6122-6129.
52. Clark JP, Munson KW, Gu JW et al: Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem 2008; 54: 2007-2017.
53. Neuhausen A, Florl AR, Grimm MO et al: DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther 2006; 5: 993-1001.
54. Catalona WJ: Management of cancer of the prostate. N Engl J Med 1994; 331: 996-1004.
55. Mahoney SE, Yao Z, Keyes CC et al: Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics 2012; 7: 400-408.